Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Ministry - Four Covid-19 Vaccines Now Available in Sudan

09/16/2021 | 06:06am EDT

The Director of the Immunisation Department of Sudan's Ministry of Health, Ismail El Adani, says that arrangements have been made to receive and facilitate storage doses of the Pfizer COVID-19 vaccine, with the installation of refrigerators that can keep the vaccine at the required minus 70 to minus 80 degrees Celsius.

El Adani said during the weekly briefing on Tuesday that the ministry has provided five refrigerators to store the Pfizer vaccine, which is now at the site of UNICEF for preparation. He indicated that the country will have four options for COVID-19 vaccines, namely Pfizer, Johnson & Johnson, AstraZeneca, and Sinopharm

El Adani pointed out that "vaccination against COVID-19 has become an international requirement. All countries are now asking that inbound travellers for proof of vaccination with one of the vaccines approved by the World Health Organization (WHO).

The Director of the Immunisation Department assured the Sudanese public that all vaccines used in Sudan are approved by the WHO. "The arrival of the AstraZeneca vaccine shipment last week, estimated at 357,000 doses, as well as the second campaign, estimated at 218,000, will cover all people in the country eligible for the second dose," and added, "The second stage is the use of the AstraZeneca vaccine."

El Adani said that the choice of this vaccine will be available to all Sudanese by early October. He said that more than 120,000 people have been vaccinated with the Johnson & Johnson vaccine in all states for the targeted groups.

The ministry has reached out to the vaccine donor platforms such as the COVAX facility, embassies, and donor countries, and the ministry was able to secure a number of vaccines that will come successively, and pointed to the expectation of the arrival of more than five million doses of the Johnson & Johnson vaccine.

He explained that the Chinese Sinopharm vaccine is more desirable for groups and students who travel to China or countries that request this vaccine.

"The main objective of the immunisation programme is for all people in Sudan to receive the vaccine in order to protect them and prevent them from being admitted to hospitals.

In the latest official figures, the Ministry of Health reports two deaths and 15 confirmed cases of coronavirus. The ministry said in its epidemiological report that Northern State recorded the largest number of injuries, with nine cases. Of the total cases, there are eight confirmed cases of travellers or visitors, four cases in Khartoum, and four in Northern State. Two COVID-19 patients died in West Kordofan and North Kordofan.

The report indicated that the active cases so far amounted to 61 cases, and 3,145 cases are under review.

Copyright Radio Dabanga. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.43% 9042 Delayed Quote.22.92%
JOHNSON & JOHNSON -1.02% 164.01 Delayed Quote.5.32%
PFIZER, INC. -1.12% 43.11 Delayed Quote.17.22%
All news about PFIZER, INC.
10:12aToday on Wall Street: It’s a numbers game
07:00aPRESS RELEASE : BioNTech to Report Third Quarter Financial Results and Operational Update ..
06:59aBristol Myers reports 10% quarterly sales growth as cancer drugs rebound
06:26aThermo Fisher lifts full-year forecast after third-quarter profit beat
05:06aCovid-19 - Unpacking South Africa's Plan to Vaccinate Adolescents
04:11aEUROPEAN MIDDAY BRIEFING - Stocks Fall After -3-
10/26Swissmedic OKs Pfizer/BioNTech COVID-19 Booster Jabs For High Risk People
10/26Pfizer, BioNTech Get US FDA Panel's Endorsement for COVID-19 Vaccine in Children 5 and ..
10/26FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the P..
10/26FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the P..
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 557 M - -
Net income 2021 18 627 M - -
Net Debt 2021 29 307 M - -
P/E ratio 2021 12,8x
Yield 2021 3,62%
Capitalization 244 B 244 B -
EV / Sales 2021 3,35x
EV / Sales 2022 3,82x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 43,56 $
Average target price 45,72 $
Spread / Average Target 4,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.17.22%244 227
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
MERCK & CO., INC.0.55%208 206